DFP-10917

Small molecule

DDelta-Fly Pharma, Inc.

DFP-10917 is one of 63 small molecule programs targeting Acute Myeloid Leukemia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Acute LeukemiaActive, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Acute LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

32 2

Vepesid

AAvyxa

Phase 3

50 3

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

31 4

Novantrone

EMD Serono

Phase 3

19 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 6

Alkeran

AApotex Inc.

Phase 3

7 7

Astplayer

AAstex Pharmaceuticals, Inc.

Phase 3

3 8

Retin-a

VValeant Pharmaceuticals

Phase 3

2 9

Campath

GGenzyme, a Sanofi Company

Leukine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·DDelta-Fly Pharma, Inc.·Phase 1/2·NCT06382168·39 enrolled

Acute Leukemia1 trial

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

Completed·DDelta-Fly Pharma, Inc.·Phase 1/2·NCT01702155·69 enrolled

Trial1 trial

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Terminated·DDelta-Fly Pharma, Inc.·Phase 3·NCT03926624·167 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DFP-10917. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DFP-10917 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DFP-10917. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Delta-Fly Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: DDelta-Fly Pharma, Inc.

DFP-10917

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Acute Leukemia1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News